The world's first Ebola vaccine! Ervebo of Merck obtains EU approval
-
Last Update: 2019-11-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Fan Dongdong 11 November Ervebo is composed of modified vesicular stomatitis virus (VSV) and important glycoprotein on the surface of Ebola virus VSV can sicken some domestic animals, but it is harmless to human beings The virus activates the immune system by producing a mild infection that causes the latter to produce antibodies against the Ebola protein Last month, the European Medicines Agency's (EMA) Committee on human drugs (CHMP) recommended conditional approval of ervebo for the prevention of Ebola related diseases in people 18 and older Before it was approved, due to the severity of the epidemic, MSD had provided a large number of research preparations in response to the request of the World Health Organization (who), and injected them in the Congo region The continuous outbreak in the country has killed nearly 2200 people With the support of CHMP, Roger Perlmutter, President of MSD research laboratory, said that the company's current "priority" is to prepare for the planned production of ervebo Now that the vaccine has been approved by European regulators, MSD will begin production at its German plant and is expected to start shipping in the third quarter of 2020 Previously, the US FDA has granted the qualification of ervebo breakthrough therapy identification and priority review, and it is expected to make a final decision on the marketing license of the vaccine in March 2020.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
